Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)

Potentiating prostate cancer immunotherapy with oncolytic viruses

Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.

Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

Current status of clinical trials assessing oncolytic virus therapy for urological cancers

A comprehensive review of immunotherapies in prostate cancer

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study